Loading...
Bandhan BSE Healthcare Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (21-Jan-25)
₹9.750.00%1D
Returns (Since Inception)
0.00%
Rated ★4.5+ on 
Fund Overview
Fund Size
₹18 Cr
Expense Ratio
1.02%
ISIN
INF194KB1IR4
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Sep 2024
About this fund
This fund has been in existence for 4 months and 16 days, having been launched on 06-Sep-24.
As of 21-Jan-25, it has a Net Asset Value (NAV) of ₹9.75, Assets Under Management (AUM) of 18.32 Crores, and an expense ratio of 1.02%.
As of 21-Jan-25, it has a Net Asset Value (NAV) of ₹9.75, Assets Under Management (AUM) of 18.32 Crores, and an expense ratio of 1.02%.
- The fund's asset allocation comprises around 100.30% in equities, 0.00% in debts, and -0.30% in cash & cash equivalents.
- You can start investing in Bandhan BSE Healthcare Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Portfolio Summaryas of 31st December 2024
| Equity | ₹18.37 Cr | 100.30% |
| Others | ₹-0.06 Cr | -0.30% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹2.8 Cr | 15.28% |
| Cipla Ltd | Equity | ₹1.17 Cr | 6.40% |
| Dr Reddy's Laboratories Ltd | Equity | ₹1.16 Cr | 6.35% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.15 Cr | 6.26% |
| Divi's Laboratories Ltd | Equity | ₹1.07 Cr | 5.84% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹1.01 Cr | 5.51% |
| Lupin Ltd | Equity | ₹0.78 Cr | 4.27% |
| Fortis Healthcare Ltd | Equity | ₹0.52 Cr | 2.82% |
| Aurobindo Pharma Ltd | Equity | ₹0.51 Cr | 2.79% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.44 Cr | 2.39% |
| Alkem Laboratories Ltd | Equity | ₹0.41 Cr | 2.23% |
| Mankind Pharma Ltd | Equity | ₹0.4 Cr | 2.17% |
| Zydus Lifesciences Ltd | Equity | ₹0.34 Cr | 1.84% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.33 Cr | 1.81% |
| Laurus Labs Ltd | Equity | ₹0.33 Cr | 1.78% |
| Ipca Laboratories Ltd | Equity | ₹0.31 Cr | 1.71% |
| Biocon Ltd | Equity | ₹0.22 Cr | 1.22% |
| Piramal Pharma Ltd | Equity | ₹0.22 Cr | 1.22% |
| Syngene International Ltd | Equity | ₹0.21 Cr | 1.17% |
| Abbott India Ltd | Equity | ₹0.21 Cr | 1.14% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.2 Cr | 1.10% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.2 Cr | 1.09% |
| Gland Pharma Ltd | Equity | ₹0.19 Cr | 1.06% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.18 Cr | 0.99% |
| Concord Biotech Ltd | Equity | ₹0.18 Cr | 0.97% |
| Ajanta Pharma Ltd | Equity | ₹0.17 Cr | 0.93% |
| Natco Pharma Ltd | Equity | ₹0.17 Cr | 0.93% |
| Neuland Laboratories Limited | Equity | ₹0.16 Cr | 0.88% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.16 Cr | 0.85% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.16 Cr | 0.85% |
| Wockhardt Ltd | Equity | ₹0.15 Cr | 0.83% |
| Poly Medicure Ltd | Equity | ₹0.13 Cr | 0.74% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.13 Cr | 0.69% |
| Global Health Ltd | Equity | ₹0.12 Cr | 0.67% |
| Granules India Ltd | Equity | ₹0.12 Cr | 0.65% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.12 Cr | 0.65% |
| Jubilant Pharmova Ltd | Equity | ₹0.12 Cr | 0.63% |
| Pfizer Ltd | Equity | ₹0.11 Cr | 0.60% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.1 Cr | 0.57% |
| Net Current Assets | Cash | ₹-0.1 Cr | 0.52% |
| Marksans Pharma Ltd | Equity | ₹0.08 Cr | 0.45% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.08 Cr | 0.44% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.08 Cr | 0.44% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.08 Cr | 0.44% |
| Sanofi India Ltd | Equity | ₹0.08 Cr | 0.41% |
| Metropolis Healthcare Ltd | Equity | ₹0.07 Cr | 0.41% |
| Onesource Specialty Pharma Limited ^ | Equity | ₹0.07 Cr | 0.40% |
| Caplin Point Laboratories Ltd | Equity | ₹0.07 Cr | 0.38% |
| Ami Organics Ltd | Equity | ₹0.07 Cr | 0.38% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.07 Cr | 0.37% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.06 Cr | 0.34% |
| Strides Pharma Science Ltd | Equity | ₹0.06 Cr | 0.34% |
| Shilpa Medicare Ltd | Equity | ₹0.06 Cr | 0.33% |
| Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.31% |
| Aarti Pharmalabs Ltd | Equity | ₹0.05 Cr | 0.25% |
| Alivus Life Sciences Ltd | Equity | ₹0.04 Cr | 0.23% |
| Indegene Ltd | Equity | ₹0.04 Cr | 0.22% |
| Triparty Repo Trp_010125 | Cash - Repurchase Agreement | ₹0.04 Cr | 0.22% |
| Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.21% |
| Orchid Pharma Ltd | Equity | ₹0.04 Cr | 0.21% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.04 Cr | 0.21% |
| FDC Ltd | Equity | ₹0.03 Cr | 0.18% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.03 Cr | 0.17% |
| Sequent Scientific Ltd | Equity | ₹0.03 Cr | 0.16% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.03 Cr | 0.15% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.15% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.03 Cr | 0.15% |
| Supriya Lifescience Ltd | Equity | ₹0.03 Cr | 0.14% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.13% |
| Innova Captab Ltd | Equity | ₹0.02 Cr | 0.13% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.02 Cr | 0.13% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.02 Cr | 0.12% |
| Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.12% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.12% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.11% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.11% |
| Thyrocare Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
| Blue Jet Healthcare Ltd | Equity | ₹0.02 Cr | 0.10% |
| Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.09% |
| Indoco Remedies Ltd | Equity | ₹0.02 Cr | 0.09% |
| Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.08% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.07% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
| RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.07% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.07% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.07% |
| Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.06% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.06% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.06% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
| NGL Fine-Chem Ltd | Equity | ₹0 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.26%
Mid Cap Stocks
27.87%
Small Cap Stocks
26.00%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹18.04 Cr | 98.51% |
| Basic Materials | ₹0.09 Cr | 0.51% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Nemish Sheth
Since September 2024
Additional Scheme Detailsas of 31st December 2024
ISIN INF194KB1IR4 | Expense Ratio 1.02% | Exit Load No Charges | Fund Size ₹18 Cr | Age 4 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹620.49 Cr | 12.9% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹620.49 Cr | 12.2% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹502.65 Cr | 4.7% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹740.33 Cr | 12.3% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1896.35 Cr | 7.5% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1301.32 Cr | 13.2% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹740.33 Cr | 13.0% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹502.65 Cr | 5.3% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1896.35 Cr | 8.1% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1301.32 Cr | 12.5% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bandhan BSE Healthcare Index Fund Regular Growth?
The NAV of Bandhan BSE Healthcare Index Fund Regular Growth, as of 21-Jan-2025, is ₹9.75.
What is the portfolio composition of Bandhan BSE Healthcare Index Fund Regular Growth?
The fund's allocation of assets is distributed as 100.30% in equities, 0.00% in bonds, and -0.30% in cash and cash equivalents.
Who manages the Bandhan BSE Healthcare Index Fund Regular Growth?
The fund managers responsible for Bandhan BSE Healthcare Index Fund Regular Growth are:-
- Nemish Sheth
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Bandhan BSE Healthcare Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (21-Jan-25)
₹9.750.00%1D
Returns (Since Inception)
0.00%
Rated ★4.5+ on
Fund Overview
Fund Size
₹18 Cr
Expense Ratio
1.02%
ISIN
INF194KB1IR4
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Sep 2024
Risk Level
Your principal amount will be at Very High Risk
About this fund
This fund has been in existence for 4 months and 16 days, having been launched on 06-Sep-24.
As of 21-Jan-25, it has a Net Asset Value (NAV) of ₹9.75, Assets Under Management (AUM) of 18.32 Crores, and an expense ratio of 1.02%.
As of 21-Jan-25, it has a Net Asset Value (NAV) of ₹9.75, Assets Under Management (AUM) of 18.32 Crores, and an expense ratio of 1.02%.
- The fund's asset allocation comprises around 100.30% in equities, 0.00% in debts, and -0.30% in cash & cash equivalents.
- You can start investing in Bandhan BSE Healthcare Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Portfolio Summaryas of 31st December 2024
| Equity | ₹18.37 Cr | 100.30% |
| Others | ₹-0.06 Cr | -0.30% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹2.8 Cr | 15.28% |
| Cipla Ltd | Equity | ₹1.17 Cr | 6.40% |
| Dr Reddy's Laboratories Ltd | Equity | ₹1.16 Cr | 6.35% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.15 Cr | 6.26% |
| Divi's Laboratories Ltd | Equity | ₹1.07 Cr | 5.84% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹1.01 Cr | 5.51% |
| Lupin Ltd | Equity | ₹0.78 Cr | 4.27% |
| Fortis Healthcare Ltd | Equity | ₹0.52 Cr | 2.82% |
| Aurobindo Pharma Ltd | Equity | ₹0.51 Cr | 2.79% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.44 Cr | 2.39% |
| Alkem Laboratories Ltd | Equity | ₹0.41 Cr | 2.23% |
| Mankind Pharma Ltd | Equity | ₹0.4 Cr | 2.17% |
| Zydus Lifesciences Ltd | Equity | ₹0.34 Cr | 1.84% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.33 Cr | 1.81% |
| Laurus Labs Ltd | Equity | ₹0.33 Cr | 1.78% |
| Ipca Laboratories Ltd | Equity | ₹0.31 Cr | 1.71% |
| Biocon Ltd | Equity | ₹0.22 Cr | 1.22% |
| Piramal Pharma Ltd | Equity | ₹0.22 Cr | 1.22% |
| Syngene International Ltd | Equity | ₹0.21 Cr | 1.17% |
| Abbott India Ltd | Equity | ₹0.21 Cr | 1.14% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.2 Cr | 1.10% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.2 Cr | 1.09% |
| Gland Pharma Ltd | Equity | ₹0.19 Cr | 1.06% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.18 Cr | 0.99% |
| Concord Biotech Ltd | Equity | ₹0.18 Cr | 0.97% |
| Ajanta Pharma Ltd | Equity | ₹0.17 Cr | 0.93% |
| Natco Pharma Ltd | Equity | ₹0.17 Cr | 0.93% |
| Neuland Laboratories Limited | Equity | ₹0.16 Cr | 0.88% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.16 Cr | 0.85% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.16 Cr | 0.85% |
| Wockhardt Ltd | Equity | ₹0.15 Cr | 0.83% |
| Poly Medicure Ltd | Equity | ₹0.13 Cr | 0.74% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.13 Cr | 0.69% |
| Global Health Ltd | Equity | ₹0.12 Cr | 0.67% |
| Granules India Ltd | Equity | ₹0.12 Cr | 0.65% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.12 Cr | 0.65% |
| Jubilant Pharmova Ltd | Equity | ₹0.12 Cr | 0.63% |
| Pfizer Ltd | Equity | ₹0.11 Cr | 0.60% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.1 Cr | 0.57% |
| Net Current Assets | Cash | ₹-0.1 Cr | 0.52% |
| Marksans Pharma Ltd | Equity | ₹0.08 Cr | 0.45% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.08 Cr | 0.44% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.08 Cr | 0.44% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.08 Cr | 0.44% |
| Sanofi India Ltd | Equity | ₹0.08 Cr | 0.41% |
| Metropolis Healthcare Ltd | Equity | ₹0.07 Cr | 0.41% |
| Onesource Specialty Pharma Limited ^ | Equity | ₹0.07 Cr | 0.40% |
| Caplin Point Laboratories Ltd | Equity | ₹0.07 Cr | 0.38% |
| Ami Organics Ltd | Equity | ₹0.07 Cr | 0.38% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.07 Cr | 0.37% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.06 Cr | 0.34% |
| Strides Pharma Science Ltd | Equity | ₹0.06 Cr | 0.34% |
| Shilpa Medicare Ltd | Equity | ₹0.06 Cr | 0.33% |
| Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.31% |
| Aarti Pharmalabs Ltd | Equity | ₹0.05 Cr | 0.25% |
| Alivus Life Sciences Ltd | Equity | ₹0.04 Cr | 0.23% |
| Indegene Ltd | Equity | ₹0.04 Cr | 0.22% |
| Triparty Repo Trp_010125 | Cash - Repurchase Agreement | ₹0.04 Cr | 0.22% |
| Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.21% |
| Orchid Pharma Ltd | Equity | ₹0.04 Cr | 0.21% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.04 Cr | 0.21% |
| FDC Ltd | Equity | ₹0.03 Cr | 0.18% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.03 Cr | 0.17% |
| Sequent Scientific Ltd | Equity | ₹0.03 Cr | 0.16% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.03 Cr | 0.15% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.15% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.03 Cr | 0.15% |
| Supriya Lifescience Ltd | Equity | ₹0.03 Cr | 0.14% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.13% |
| Innova Captab Ltd | Equity | ₹0.02 Cr | 0.13% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.02 Cr | 0.13% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.02 Cr | 0.12% |
| Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.12% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.12% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.11% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.11% |
| Thyrocare Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
| Blue Jet Healthcare Ltd | Equity | ₹0.02 Cr | 0.10% |
| Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.09% |
| Indoco Remedies Ltd | Equity | ₹0.02 Cr | 0.09% |
| Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.08% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.07% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
| RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.07% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.07% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.07% |
| Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.06% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.06% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.06% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
| NGL Fine-Chem Ltd | Equity | ₹0 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.26%
Mid Cap Stocks
27.87%
Small Cap Stocks
26.00%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹18.04 Cr | 98.51% |
| Basic Materials | ₹0.09 Cr | 0.51% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Nemish Sheth
Since September 2024
Additional Scheme Detailsas of 31st December 2024
ISIN INF194KB1IR4 | Expense Ratio 1.02% | Exit Load No Charges | Fund Size ₹18 Cr | Age 4 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹620.49 Cr | 12.9% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹620.49 Cr | 12.2% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹502.65 Cr | 4.7% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹740.33 Cr | 12.3% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1896.35 Cr | 7.5% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1301.32 Cr | 13.2% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹740.33 Cr | 13.0% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹502.65 Cr | 5.3% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1896.35 Cr | 8.1% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1301.32 Cr | 12.5% |
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bandhan BSE Healthcare Index Fund Regular Growth?
The NAV of Bandhan BSE Healthcare Index Fund Regular Growth, as of 21-Jan-2025, is ₹9.75.
What is the portfolio composition of Bandhan BSE Healthcare Index Fund Regular Growth?
The fund's allocation of assets is distributed as 100.30% in equities, 0.00% in bonds, and -0.30% in cash and cash equivalents.
Who manages the Bandhan BSE Healthcare Index Fund Regular Growth?
The fund managers responsible for Bandhan BSE Healthcare Index Fund Regular Growth are:-
- Nemish Sheth
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2024 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts